US 12,006,522 B2
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
Gary Owens, Durham, NC (US); Janel Lape, Wake Forest, NC (US); James Jefferson Smith, Morrisville, NC (US); John Morris, Raleigh, NC (US); Caitlin Turner, Durham, NC (US); Whitney Lewis, Oxford, NC (US); and Derek Jantz, Durham, NC (US)
Assigned to Precision BioSciences, Inc., Durham, NC (US)
Filed by Precision BioSciences, Inc., Durham, NC (US)
Filed on Jul. 27, 2023, as Appl. No. 18/360,312.
Application 18/360,312 is a division of application No. 17/931,896, filed on Sep. 13, 2022, granted, now 11,753,630.
Application 17/931,896 is a continuation of application No. PCT/US2021/059146, filed on Nov. 12, 2021.
Claims priority of provisional application 63/233,664, filed on Aug. 16, 2021.
Claims priority of provisional application 63/113,131, filed on Nov. 12, 2020.
Prior Publication US 2024/0018495 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C12N 15/86 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 15/86 (2013.01); C12N 2750/14143 (2013.01)] 16 Claims
 
1. A polynucleotide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a nucleic acid at a site that comprises a recognition sequence consisting of the nucleic acid sequence of SEQ ID NO: 6 in a dystrophin gene, wherein said engineered meganuclease comprises the amino acid sequence of SEQ ID NO: 43.